INT94543

Context Info Confidence 0.29 First Reported 2001 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 0.96 Pain Relevance 0.36

cytosol (MT2A) nucleus (MT2A) cytoplasm (MT2A)

Anatomy Link Frequency MT2 3 bladder 1 bile 1 MT2A (Homo sapiens)

Pain Link Frequency Relevance Heat agonist 60 99.12 Bile 9 98.64 interstitial cystitis 1 92.44 Bioavailability 9 19.56 GABAergic 24 5.00 withdrawal 13 5.00 Serotonin 12 5.00 depression 9 5.00 Inflammation 9 5.00 addiction 9 5.00

Disease Link Frequency Relevance Heat Bladder Cancer 9 94.40 Bladder Disease 1 94.04 Cystitis 3 92.96 Toxicity 16 92.56 Interstitial Cystitis 1 92.44 Body Weight 1 81.84 Carcinoma In Situ 1 75.84 Argyria 56 63.20 Cancer 6 58.80 Sleep Initiation And Maintenance Disorders 72 50.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Immunohistochemical analysis disclosed no immunoreactivity for MT-1 and MT-2 (designated as MT-1/2 to reflect the nonspecificity of the antibody for the two isoforms) in cells comprising the normal bladder or in nonmalignant bladder disorders, such as cystitis and interstitial cystitis.

MT-2 Neg (no) Binding (immunoreactivity) of in bladder associated with cystitis, interstitial cystitis and bladder disease

1) Confidence 0.29 Published 2001 Journal Cancer Detect. Prev. Section Abstract Doc Link 11270423 Disease Relevance 0.72 Pain Relevance 0.09

This agonist developed by Eli Lilly also diplays a high affinity towards MT1 und MT2 receptors (Ki = 81 pM for MT1 bzw. 42 pM for MT2).

MT2 Binding (affinity) of in MT2 associated with agonist

2) Confidence 0.15 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2699659 Disease Relevance 0 Pain Relevance 0.05

This agonist developed by Eli Lilly also diplays a high affinity towards MT1 und MT2 receptors (Ki = 81 pM for MT1 bzw. 42 pM for MT2).

MT2 Binding (affinity) of in MT2 associated with agonist

3) Confidence 0.13 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2699659 Disease Relevance 0 Pain Relevance 0.05

The preferential binding to MT2 is typical for the 6-chlorinated melatonin derivatives, and also seen with 6-chloromelatonin.47 Because of the substitution at C-atom 6, this drug cannot be converted by the respective CYP isoforms to 6-hydroxymelatonin and its half-life in the circulation is, therefore, extended.47,62 Although ?

MT2 Binding (binding) of in MT2

4) Confidence 0.13 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2699659 Disease Relevance 0 Pain Relevance 0.05

As in other tissues, Ag+ evokes and binds MT-1 and MT-2 and is eliminated innocuously in bile without morphological change [101].

MT-2 Binding (binds) of in bile associated with bile

5) Confidence 0.04 Published 2010 Journal Advances in Pharmacological Sciences Section Body Doc Link PMC3003978 Disease Relevance 0.24 Pain Relevance 0.12

General Comments

This test has worked.